DAFNA Capital Management LLC Has $1.27 Million Position in iTeos Therapeutics, Inc. $ITOS

Key Points

• DAFNA Capital Management LLC increased its stake in iTeos Therapeutics by 13.3% during the first quarter, owning approximately $1.27 million worth of the company's stock.
• Analyst ratings for iTeos Therapeutics have varied, with Wall Street Zen recently assigning a "sell" rating, while the average target price has dropped to $15.50 from higher previous estimates.
• Following a disappointing earnings report, iTeos Therapeutics recorded an Earnings Per Share (EPS) of ($1.51), missing the consensus estimate by $0.39.

DAFNA Capital Management LLC increased its position in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 13.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 213,347 shares of the company's stock after buying an additional 25,000 shares during the period. DAFNA Capital Management LLC owned 0.56% of iTeos Therapeutics worth $1,274,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in ITOS. Point72 Asia Singapore Pte. Ltd. acquired a new position in iTeos Therapeutics in the fourth quarter worth approximately $42,000. CWM LLC increased its holdings in iTeos Therapeutics by 428.7% in the first quarter. CWM LLC now owns 8,554 shares of the company's stock worth $51,000 after buying an additional 6,936 shares during the last quarter. Forefront Analytics LLC acquired a new position in iTeos Therapeutics in the fourth quarter worth approximately $85,000. Graham Capital Management L.P. acquired a new position in iTeos Therapeutics in the fourth quarter worth approximately $85,000. Finally, Ieq Capital LLC acquired a new position in iTeos Therapeutics in the first quarter worth approximately $88,000. Institutional investors and hedge funds own 97.16% of the company's stock.

iTeos Therapeutics Stock Performance

Shares of NASDAQ ITOS remained flat at $10.15 during trading hours on Wednesday. The firm has a market cap of $448.73 million, a PE ratio of -2.17 and a beta of 1.31. iTeos Therapeutics, Inc. has a twelve month low of $4.80 and a twelve month high of $17.63. The business's 50 day simple moving average is $10.14 and its 200-day simple moving average is $8.47.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($1.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.39). Sell-side analysts expect that iTeos Therapeutics, Inc. will post -3.49 EPS for the current year.

Insiders Place Their Bets

In related news, Director David Hallal sold 38,228 shares of the firm's stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $10.24, for a total transaction of $391,454.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michel Detheux sold 43,883 shares of the stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $10.02, for a total value of $439,707.66. Following the transaction, the chief executive officer owned 153,903 shares of the company's stock, valued at $1,542,108.06. This represents a 22.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 224,902 shares of company stock valued at $2,277,354. Corporate insiders own 14.20% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on ITOS shares. Raymond James Financial set a $12.00 price objective on iTeos Therapeutics in a report on Wednesday, May 14th. Leerink Partnrs downgraded iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 14th. Wall Street Zen upgraded iTeos Therapeutics to a "sell" rating in a report on Saturday. Piper Sandler cut iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Monday, July 21st. Finally, Wells Fargo & Company decreased their target price on iTeos Therapeutics from $12.00 to $11.00 and set an "equal weight" rating for the company in a research report on Thursday, August 7th. One equities research analyst has rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $15.50.

iTeos Therapeutics Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.